The challenge is finding those changes accurately.

This is where mitochondrial variant calling becomes valuable. By analyzing sequencing data for changes in mtDNA, researchers can identify potential disease-associated variants, examine heteroplasmy, and investigate genetic clues that may otherwise be missed.

Why Mitochondrial DNA Is Different

Most genomic analysis focuses on DNA inside the cell nucleus. Mitochondria are different because they carry their own small, circular genome.

Human mtDNA contains 37 genes involved in mitochondrial function, including genes important for oxidative phosphorylation and protein production. But there is another feature that makes mitochondrial genetics particularly interesting: cells contain multiple copies of mtDNA, and those copies may not all be identical.

This mixture is known as heteroplasmy.

For example, if 20 out of 100 copies of mtDNA carry a particular variant, the variant has around 20% heteroplasmy. The biological significance, however, cannot be determined from that percentage alone.

The level of a variant can vary between tissues, and its effect can depend on the specific variant and other biological factors.

What Does Mitochondrial Variant Calling Do?

Put simply, variant calling identifies differences between sequencing reads and a reference mitochondrial genome.

A mitochondrial variant calling workflow can include:

• Sequencing quality control
• Alignment of reads to the mitochondrial genome
• Detection of SNVs and small indels
• Heteroplasmy estimation
• Detection of larger mitochondrial deletions
• Variant annotation and prioritization

There is also a less obvious challenge: NUMTs, or nuclear mitochondrial DNA segments. These are mitochondrial-like sequences located in the nuclear genome and can complicate read alignment and variant detection.

That means mitochondrial analysis needs more than simply detecting a difference in a sequence. The workflow must consider how mtDNA behaves and how sequencing reads map across the genome.

For research teams working with NGS data, a structured variant calling workflow can help organize these steps and move from sequencing reads toward variants that can be investigated further.

What Does Recent Research Show?

A 2025 study by Sarah L. Stenton and colleagues provides a useful example.

The researchers analyzed mitochondrial DNA from 6,660 rare-disease families using exome and genome sequencing data. Their systematic analysis identified diagnostic mitochondrial variants in 10 previously undiagnosed families, including a large deletion and several pathogenic or likely pathogenic variants.

The study is particularly useful because the researchers designed dedicated pipelines to address mitochondrial-specific challenges such as the circular genome, heteroplasmy, and nuclear misalignment. Read the 2025 study on PubMed

The finding highlights something easy to overlook: the mitochondrial genome can contain answers that may not be found through nuclear genome analysis alone.

Of course, not every unexplained disease case has a mitochondrial cause. But the study demonstrates why mtDNA analysis can be a valuable part of broader rare-disease research, alongside approaches such as trio exome sequencing for rare diseases.

Why Heteroplasmy Matters

One of the most interesting parts of mitochondrial variant analysis is that a variant is not always simply present or absent.

The proportion of altered mtDNA can matter.

A variant detected at a low level may have a different biological significance from the same variant detected at a higher level. However, there is no single heteroplasmy percentage that can be used as a universal threshold for disease.

Tissue can matter too. A variant may appear at different levels in blood and other tissues, which is why researchers need to interpret heteroplasmy in the appropriate biological context.

This is also why variant calling should not be treated as the final answer. It produces findings that need to be annotated, interpreted, and supported by additional evidence.

From Variant Detection to Research Insight

Once potential mitochondrial variants are identified, researchers can investigate what those variants might mean.

This can involve comparing findings with population databases, disease databases, computational predictions, phenotype information, and functional evidence. Researchers may also consider factors such as maternal inheritance, haplogroup background, heteroplasmy, and experimental evidence when evaluating mtDNA variants.

For a rare-disease research project, this creates a more complete picture. Instead of looking only for nuclear variants, researchers can also examine mitochondrial changes and determine whether they provide a plausible explanation for the observed phenotype.

Where Bioinformatics Fits In

The biology may be complex, but the analysis workflow does not have to become unnecessarily difficult for researchers.

Platforms such as GenomeBeans can support sequencing data analysis through structured bioinformatics workflows, helping research teams move from raw sequencing data toward organized variant results and downstream interpretation.

For mitochondrial research, the important point is not simply generating a list of variants. It is creating a workflow that accounts for heteroplasmy, mtDNA-specific challenges, annotation, and biological context.

Looking Beyond the Nuclear Genome

Mitochondrial DNA represents only a small part of the human genome, but its role in disease research can be significant.

Mitochondrial variant calling gives researchers another way to look for genetic clues when investigating unexplained disease. Combined with careful annotation and biological interpretation, it can help uncover variants that might otherwise remain outside the analysis.

As exome and genome sequencing become increasingly common in rare-disease research, giving the mitochondrial genome the attention it deserves could make genomic analysis more complete.